Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659478 | 1.00 | CA12 (0.42) | CA12CA9RAB9AHTTSMN1; SMN2 | |
| SCHEMBL4939340 | 0.81 | MEN1 (0.37) | RAB9AHTTSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4939345 | 0.81 | MEN1 (0.37) | RAB9AHTTSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4627759 | 0.77 | PTGS1 (0.47) | CA12CA9RAB9AMEN1KMT2A | |
| SCHEMBL5645876 | 0.77 | PTGS1 (0.50) | RAB9ASMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL5645747 | 0.77 | PTGS1 (0.50) | RAB9ASMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL4627757 | 0.77 | PTGS1 (0.47) | CA12CA9RAB9AMEN1KMT2A | |
| SCHEMBL14183663 | 0.73 | CA12 (0.33) | CA12CA9 | |
| SCHEMBL1775432 | 0.71 | KMT2A (0.56) | CA12CA9RAB9AHTTSMN1; SMN2 | |
| SCHEMBL4486603 | 0.71 | GLA (0.44) | RAB9AHTTSMN1; SMN2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7462721-B2 | Aza-quinolinol phosphonate integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462721-B2 | Aza-quinolinol phosphonate integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | TYMP, MTAP, PNP | CA12 4221/4885CA9 4267/4885RAB9A 3329/4885 |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | CA12 2670/4885CA9 1097/4885RAB9A 1186/4885 |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | CDKL5, CDKL1, CDKL3 | CA12 4845/4885CA9 4441/4885RAB9A 2064/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | CA12 4829/4885CA9 4534/4885RAB9A 2959/4885 |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | CA12 770/4885CA9 108/4885RAB9A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.